Special Issue

Novel Metal-Based Drugs for Anticancer and Antiviral Applications

Message from the Guest Editors

The discovery of the antiproliferative properties of cisplatin and its subsequent use in cancer treatment has attracted great interest in the family of transition metal complexes. The coordination numbers and geometries, the different available redox states, and the various kinetic properties of transition metal complexes result in a variety of opportunities in the design of new metal-based drugs. Moreover, the broad potential of transition metal complexes has attracted great interest from researchers, originating new points of view and new perspectives for their use in a large range of applications, also beyond the original anticancer purposes. Against this backdrop, this Special Issue aims to collect research articles, comprehensive reviews, and short communications focused on the design, synthesis, and preclinical or clinical evidence of novel metal-based drugs for anticancer and antiviral applications. metal complexes antitumor antiviral coordination compounds metal-based drugs

Guest Editors

Dr. Federica De Castro

Department of Biological and Environmental Sciences and Technologies, University of Salento, Piazza Tancredi, 7, 73100 Lecce, LE, Italy

Dr. Damiano Cirri

Department of Chemistry and Industrial Chemistry, University of Pisa, Via Moruzzi 13, 56124 Pisa, Italy

Deadline for manuscript submissions

closed (31 January 2023)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/115678

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

